July 8, 2016—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, is expanding its U.S. headquarters in Durham, NC as well as its new European headquarters, IPM Biotech in Hamburg, Germany. BioAgilytix completed the acquisition of IPM Biotech in early 2016 and immediately set forth plans to build out a new advanced laboratory facility for its subsidiary, which will allow the company to expand IPM’s already robust platform suite to better support its European customers. BioAgilytix is also continuing expansion of its North Carolina-based GLP / GMP laboratory, taking a proactive approach to meeting growing customer demands for preclinical, clinical, and manufacturing support for pharmacokinetic, immunogenicity, cell-based assay, and biomarker studies. The expanded footprint will enable BioAgilytix to continue to ensure it has the high-quality resources in place to best serve those needs.
Construction of the new European lab space began in early spring and is on track for completion and opening this fall. While IPM Biotech currently operates in a GLP laboratory, its new site will add GMP certification as well as duplicate platforms already available in BioAgilytix’s U.S. laboratory. This will give customers ready access to BioAgilytix’s top-caliber technology, scientific quality, and regulatory expertise on both continents—and the same high-quality results from either lab that supports them.
The expansion of BioAgilytix’s U.S. lab space began in late spring and will also be completed in 2016, with construction now underway to complete a 19,000+ square foot addition to its premier facility. Not only will this expansion help to further increase efficiencies, but also enables BioAgilytix to continue to methodically grow its scientific team, adding more breadth and depth of expertise for customers to leverage.
Leadership from both BioAgilytix and IPM Biotech feel these expansions will help their team continue to give customers in Europe and North America the best bioanalytical lab experience possible. “The addition of IPM Biotech expanded our European presence to more easily support global customers,” said Jim Datin, CEO of BioAgilytix. “This new facility will now enhance that presence as the most technologically advanced bioanalytical laboratory in Europe supporting biotherapeutics development.” Dr. Arno Kromminga, CSO of IPM Biotech, stated that “it has been a very positive experience integrating the IPM and BioAgilytix teams, because we both uphold a strong commitment to scientific rigor, quality, and customer service. This has made it easy to come together as one robust team—and we are all looking forward to continuing to grow our talent in our new and expanded facilities.”
###
Services
Platforms